Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia

Andrew H. Baker, Vincenzo Sica, Lorraine M. Work, Sharon Williams-Ignarro, Filomena De Nigris, Lilach O Lerman, Amelia Casamassimi, Alessandro Lanza, Concetta Schiano, Monica Rienzo, Louis J. Ignarro, Claudio Napoli

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Despite advances in imaging, understanding the underlying pathways, and clinical translation of animal models of disease there remains an urgent need for therapies that reduce brain damage after stroke and promote functional recovery in patients. Blocking oxidant radicals, reducing matrix metalloproteinase-induced neuronal damage, and use of stem cell therapy have been proposed and tested individually in prior studies. Here we provide a comprehensive integrative management approach to reducing damage and promoting recovery by combining biological therapies targeting these areas. In a rat model of transient cerebral ischemia (middle cerebral artery occlusion) gene delivery vectors were used to overexpress tissue inhibitor of matrix metalloproteinase 1 and 2 (TIMP1 and TIMP2) 3 days before ischemia. After occlusion, autologous bone marrow cells alone or in combination with agents to improve NO bioavailability were administered intraarterially. When infarct size, BrdU incorporation, and motor function recovery were determined in the treatment groups the largest beneficial effect was seen in rats receiving the triple combined therapy, surpassing effects of single or double therapies. Our study highlights the utility of combined drug, gene, and cell therapy in the treatment of stroke.

Original languageEnglish (US)
Pages (from-to)3597-3602
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume104
Issue number9
DOIs
StatePublished - Feb 27 2007

Fingerprint

Metalloproteases
Brain Ischemia
Bone Marrow Cells
Brain
Cell- and Tissue-Based Therapy
Stroke
Therapeutics
Animal Disease Models
Tissue Inhibitor of Metalloproteinase-2
Matrix Metalloproteinase 1
Biological Therapy
Tissue Inhibitor of Metalloproteinase-1
Critical Pathways
Middle Cerebral Artery Infarction
Matrix Metalloproteinase 2
Transient Ischemic Attack
Recovery of Function
Bromodeoxyuridine
Matrix Metalloproteinases
Oxidants

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia. / Baker, Andrew H.; Sica, Vincenzo; Work, Lorraine M.; Williams-Ignarro, Sharon; De Nigris, Filomena; Lerman, Lilach O; Casamassimi, Amelia; Lanza, Alessandro; Schiano, Concetta; Rienzo, Monica; Ignarro, Louis J.; Napoli, Claudio.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, No. 9, 27.02.2007, p. 3597-3602.

Research output: Contribution to journalArticle

Baker, AH, Sica, V, Work, LM, Williams-Ignarro, S, De Nigris, F, Lerman, LO, Casamassimi, A, Lanza, A, Schiano, C, Rienzo, M, Ignarro, LJ & Napoli, C 2007, 'Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia', Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 9, pp. 3597-3602. https://doi.org/10.1073/pnas.0611112104
Baker, Andrew H. ; Sica, Vincenzo ; Work, Lorraine M. ; Williams-Ignarro, Sharon ; De Nigris, Filomena ; Lerman, Lilach O ; Casamassimi, Amelia ; Lanza, Alessandro ; Schiano, Concetta ; Rienzo, Monica ; Ignarro, Louis J. ; Napoli, Claudio. / Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia. In: Proceedings of the National Academy of Sciences of the United States of America. 2007 ; Vol. 104, No. 9. pp. 3597-3602.
@article{1b3c8dcf9abc4109941e5e1aca021158,
title = "Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia",
abstract = "Despite advances in imaging, understanding the underlying pathways, and clinical translation of animal models of disease there remains an urgent need for therapies that reduce brain damage after stroke and promote functional recovery in patients. Blocking oxidant radicals, reducing matrix metalloproteinase-induced neuronal damage, and use of stem cell therapy have been proposed and tested individually in prior studies. Here we provide a comprehensive integrative management approach to reducing damage and promoting recovery by combining biological therapies targeting these areas. In a rat model of transient cerebral ischemia (middle cerebral artery occlusion) gene delivery vectors were used to overexpress tissue inhibitor of matrix metalloproteinase 1 and 2 (TIMP1 and TIMP2) 3 days before ischemia. After occlusion, autologous bone marrow cells alone or in combination with agents to improve NO bioavailability were administered intraarterially. When infarct size, BrdU incorporation, and motor function recovery were determined in the treatment groups the largest beneficial effect was seen in rats receiving the triple combined therapy, surpassing effects of single or double therapies. Our study highlights the utility of combined drug, gene, and cell therapy in the treatment of stroke.",
author = "Baker, {Andrew H.} and Vincenzo Sica and Work, {Lorraine M.} and Sharon Williams-Ignarro and {De Nigris}, Filomena and Lerman, {Lilach O} and Amelia Casamassimi and Alessandro Lanza and Concetta Schiano and Monica Rienzo and Ignarro, {Louis J.} and Claudio Napoli",
year = "2007",
month = "2",
day = "27",
doi = "10.1073/pnas.0611112104",
language = "English (US)",
volume = "104",
pages = "3597--3602",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "9",

}

TY - JOUR

T1 - Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia

AU - Baker, Andrew H.

AU - Sica, Vincenzo

AU - Work, Lorraine M.

AU - Williams-Ignarro, Sharon

AU - De Nigris, Filomena

AU - Lerman, Lilach O

AU - Casamassimi, Amelia

AU - Lanza, Alessandro

AU - Schiano, Concetta

AU - Rienzo, Monica

AU - Ignarro, Louis J.

AU - Napoli, Claudio

PY - 2007/2/27

Y1 - 2007/2/27

N2 - Despite advances in imaging, understanding the underlying pathways, and clinical translation of animal models of disease there remains an urgent need for therapies that reduce brain damage after stroke and promote functional recovery in patients. Blocking oxidant radicals, reducing matrix metalloproteinase-induced neuronal damage, and use of stem cell therapy have been proposed and tested individually in prior studies. Here we provide a comprehensive integrative management approach to reducing damage and promoting recovery by combining biological therapies targeting these areas. In a rat model of transient cerebral ischemia (middle cerebral artery occlusion) gene delivery vectors were used to overexpress tissue inhibitor of matrix metalloproteinase 1 and 2 (TIMP1 and TIMP2) 3 days before ischemia. After occlusion, autologous bone marrow cells alone or in combination with agents to improve NO bioavailability were administered intraarterially. When infarct size, BrdU incorporation, and motor function recovery were determined in the treatment groups the largest beneficial effect was seen in rats receiving the triple combined therapy, surpassing effects of single or double therapies. Our study highlights the utility of combined drug, gene, and cell therapy in the treatment of stroke.

AB - Despite advances in imaging, understanding the underlying pathways, and clinical translation of animal models of disease there remains an urgent need for therapies that reduce brain damage after stroke and promote functional recovery in patients. Blocking oxidant radicals, reducing matrix metalloproteinase-induced neuronal damage, and use of stem cell therapy have been proposed and tested individually in prior studies. Here we provide a comprehensive integrative management approach to reducing damage and promoting recovery by combining biological therapies targeting these areas. In a rat model of transient cerebral ischemia (middle cerebral artery occlusion) gene delivery vectors were used to overexpress tissue inhibitor of matrix metalloproteinase 1 and 2 (TIMP1 and TIMP2) 3 days before ischemia. After occlusion, autologous bone marrow cells alone or in combination with agents to improve NO bioavailability were administered intraarterially. When infarct size, BrdU incorporation, and motor function recovery were determined in the treatment groups the largest beneficial effect was seen in rats receiving the triple combined therapy, surpassing effects of single or double therapies. Our study highlights the utility of combined drug, gene, and cell therapy in the treatment of stroke.

UR - http://www.scopus.com/inward/record.url?scp=33847680458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847680458&partnerID=8YFLogxK

U2 - 10.1073/pnas.0611112104

DO - 10.1073/pnas.0611112104

M3 - Article

C2 - 17360688

AN - SCOPUS:33847680458

VL - 104

SP - 3597

EP - 3602

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 9

ER -